Compare ULCC & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ULCC | NEO |
|---|---|---|
| Founded | 1994 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2021 | 1999 |
| Metric | ULCC | NEO |
|---|---|---|
| Price | $4.90 | $11.77 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 9 |
| Target Price | $5.56 | ★ $11.38 |
| AVG Volume (30 Days) | ★ 5.1M | 1.7M |
| Earning Date | 02-06-2026 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,729,000,000.00 | $709,162,000.00 |
| Revenue This Year | $0.37 | $10.90 |
| Revenue Next Year | $14.59 | $9.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 1.77 | ★ 10.10 |
| 52 Week Low | $2.89 | $4.72 |
| 52 Week High | $10.26 | $19.12 |
| Indicator | ULCC | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 50.71 | 57.42 |
| Support Level | $4.89 | $11.46 |
| Resistance Level | $5.57 | $12.19 |
| Average True Range (ATR) | 0.36 | 0.37 |
| MACD | -0.06 | -0.11 |
| Stochastic Oscillator | 25.00 | 38.13 |
Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. Majority of revenue is from Domestic flight follow by International.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.